Exelixis
EXEL
#1696
Rank
โ‚น841.00 B
Marketcap
โ‚น2,945
Share price
-3.83%
Change (1 day)
51.94%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): โ‚น50.05 Billion

According to Exelixis's latest financial reports the company's current earnings are โ‚น2.08 Billion. In 2023 the company made an earning of โ‚น21.86 Billion, an increase over its 2022 earnings that were of โ‚น19.89 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) โ‚น50.05 B128.96%
2023 โ‚น21.86 B9.89%
2022 โ‚น19.89 B-20.33%
2021 โ‚น24.97 B124.82%
2020 โ‚น11.10 B-67.14%
2019 โ‚น33.79 B-11.94%
2018 โ‚น38.37 B185.09%
2017 โ‚น13.46 B-325.82%
2016 -โ‚น5.97 Billion-58.12%
2015 -โ‚น14.24 Billion-37.61%
2014 -โ‚น22.82 Billion9.75%
2013 -โ‚น20.79 Billion65.96%
2012 -โ‚น12.53 Billion-291.63%
2011 โ‚น6.53 B-195.59%
2010 -โ‚น6.84 Billion-42.17%
2009 -โ‚น11.83 Billion-18.98%
2008 -โ‚น14.6 Billion-6.99%
2007 -โ‚น15.7 Billion46.3%
2006 -โ‚น10.73 Billion33.25%
2005 -โ‚น8.05 Billion-30.92%
2004 -โ‚น11.66 Billion44.29%
2003 -โ‚น8.08 Billion12.86%
2002 -โ‚น7.16 Billion22.79%
2001 -โ‚น5.83 Billion60.14%
2000 -โ‚น3.64 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
โ‚น354.07 B 595.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น628.86 B 1,134.83%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น1.271 T 2,395.89%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น584.06 Billion-1,246.85%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น397.20 B 679.96%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.561 T 2,966.31%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น589.40 B 1,057.35%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น3.81 Billion-107.47%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น2.47 Billion-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA